Eli Lilly: Turning Dementia Into a Zyprexa Sales Opportunity

Eli Lilly and Company agreed to pay up to $800 million in a civil settlement over alleged off-label promotion that included elderly residents with dementia. In the Eli Lilly Zyprexa nursing homes fraud case, the government alleged that Lilly pushed its antipsychotic into nursing homes and assisted-living facilities, causing public health programs to receive claims for uses they did not cover. Former Lilly sales representatives brought the whistleblower cases.

The Department of Justice announced the settlement on January 15, 2009. The nursing-home campaign was part of a wider promotion case that reached other patients and other treatment settings. The civil payment covered that broader conduct.

Zyprexa Promotion in Nursing Homes

The government alleged that Lilly devoted substantial resources to promoting Zyprexa in nursing homes and assisted living, primarily through its long-term-care sales force, beginning in 1999. The sales targets included doctors treating dementia and Alzheimer’s dementia, depression, anxiety and sleep problems, as well as agitation, aggression and hostility.

Zyprexa, also called olanzapine, is an antipsychotic. The announcement described Food and Drug Administration approvals for psychotic disorders and, later, schizophrenia and acute manic episodes associated with Bipolar I Disorder. At the time of the announcement, it had never been approved for dementia, the very condition Lilly allegedly sent its long-term-care sales force to sell it for.

The government’s account put management behind the sales message. It alleged that Lilly created marketing materials for unapproved uses, trained sales personnel and directed them to promote those uses. The government alleged Lilly was building a market around the conditions its representatives encountered in long-term care.

That strategy then reached primary care. According to the Justice Department, Lilly began targeting primary-care physicians in October 2000 and trained representatives to focus on symptoms rather than the drug’s approved indications. A symptom gave the representative a way into the conversation even when the approved diagnosis was missing.

How the Promotion Became a Public Drug Bill

The civil case alleged that Lilly’s marketing caused false payment claims to Medicaid, TRICARE and the Federal Employee Health Benefits Program for uses those programs did not cover. That connection between the sales campaign and the public bill was the False Claims Act allegation.

The whistleblower lawsuits covered alleged promotion from September 1999 through the end of 2005, involving patients of all ages. The same complaints, as described by the Justice Department, alleged that Lilly funded continuing medical education through millions of dollars in grants to promote off-label uses.

The alleged message therefore traveled through both the sales force and physician education. To someone inside the business, the training materials and grant decisions could explain why doctors were hearing a particular pitch. The prescription and payment records would show where that pitch led.

Taxpayers allegedly paid for prescriptions generated by that campaign. Elderly residents with dementia were the sales opportunity, despite the absence of approval to treat their condition. The commercial goal was more prescriptions. The resident needed a treatment chosen for their care.

The Civil Settlement and the Sales Representatives Who Brought the Cases

The civil settlement resolved four qui tam cases brought by former Lilly sales representatives. The Justice Department announced a collective award of about $78.9 million to the whistleblowers from the federal civil share. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Lilly also had to publish information about payments to doctors, including honoraria, travel and lodging. That requirement put the financial relationship between the company and prescribers in public view.

What Evidence Is Needed to Prove Fraud?

For a drug-promotion case, the evidence connects the company’s message, the people directing it, the prescription and the government payment. We work with nursing-home staff, pharmacy employees and sales insiders to build that account across the clinical and commercial sides of the business.

A sales employee may know what management taught representatives to say. A clinician may recognize the gap between the resident’s condition and the reason recorded for treatment. A pharmacy employee may understand how a recommendation became a prescription. Those different views can help us trace a campaign from the sales meeting to the resident and the public bill.

We examine the training and marketing materials alongside clinical notes, prescriptions and billing records. Where physician education carried the pitch, we examine what the company funded. The point is to establish who directed the message, how it influenced treatment and what the government paid for. That is the work we do with an insider, drawing on what they know about their part of the business.

When the Diagnosis Serves the Prescription

In a separate March 2026 review of nursing-home inspections, the HHS Office of Inspector General found instances of medical directors making inappropriate schizophrenia diagnoses to justify antipsychotic prescriptions and homes using those diagnoses to inflate star ratings. Residents diagnosed with schizophrenia were excluded from the antipsychotic quality measure, giving homes an incentive to change the diagnosis.

The inspector general also explained why the prescribing matters to residents: antipsychotics can have a sedative effect and might serve as chemical restraints to control behavior. These drugs pose an increased risk of death for elderly patients with dementia. For a nursing-home insider, the reason behind the diagnosis and the prescription belongs in the conversation about suspected misuse.

The Pharmacy Can Carry the Sales Message

The neighboring Abbott Laboratories Depakote case shows another route into the same market. Its resolution included nursing-home promotion for agitation and aggression in dementia and allegations of payments to long-term-care pharmacies.

A whistleblower’s second amended complaint in that case alleged that pharmacy-branded materials disguised the manufacturer’s promotional message:

That allegation gives a nursing-home clinician a concrete point of recognition: material carrying a pharmacy’s name may carry a drug manufacturer’s sales message. The commercial decisions influencing a resident’s medication can begin outside the home. We examine those relationships alongside the prescription and payment, including what a consultant pharmacist was asked to recommend and who stood to benefit.

You Know What Reached the Resident

If you saw dementia symptoms turned into sales targets, diagnoses changed to justify prescriptions, or pharmacy recommendations shaped by a drug campaign, speak to one of our whistleblower experts about what reached your residents. We work with you to build your strongest case, bring in pharmaceutical fraud whistleblower lawyers who understand nursing-home prescribing and off-label promotion, and stay with you throughout the case.